ACTIMED THERAPEUTICS
Generated by Meeveem AI
"Developing novel therapies to reverse muscle wasting in cachexia and serious chronic illness"
Ascot
•11 - 50 Employees
•Pharmaceuticals
About ACTIMED THERAPEUTICS
Actimed Therapeutics develops pharmaceutical treatments for cachexia and muscle wasting disorders that affect patients with cancer and other serious chronic conditions. The company's lead candidate, S-pindolol benzoate, is an Anabolic Catabolic Transforming Agent designed to reduce catabolism, increase muscle mass, improve appetite, and decrease fatigue. Cancer cachexia affects vulnerable populations with limited treatment options and no globally approved therapies. Actimed's clinical stage pipeline targets this unmet need, with Phase 2b/3 trials planned for non-small cell lung and colorectal cancer patients. The company also addresses muscle loss in obesity and weight loss treatments.
14
Team Members
2017
Founded
Pharmaceuticals
Sector
Hybrid
Work Environment
Our Vision
A world where patients with cachexia and muscle wasting diseases receive transformative care that prolongs life, restores dignity, and eases the burden on those who care for them.
Our Mission
Actimed Therapeutics brings innovation to the treatment of muscle wasting disorders, particularly cancer-related cachexia, to transform care for under-served patients.